Peptide record

TPDB92402

Z-2 Antibacterial Anticancer Toxicity iDPPIV modified_plain modified
5 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

Standard-residue backbone model; source-recorded chemical modifications are not verified in these coordinates.

TPDB92402
Z-2
Antibacterial Anticancer Toxicity iDPPIV
Anti-infective peptides Cardiometabolic peptides Cancer-related peptides Toxicity and safety peptides
Peptipedia CancerPPD 2.0 iDPPIV pep-lab
modified_plain
Yes
A 5-aa modified multi-activity (Antibacterial, Anticancer, Toxicity, and other sources) peptide sequence curated from Peptipedia, CancerPPD 2.0, iDPPIV, and other sources, with an available 3D structural model.
C-terminal: Cyclized N-terminal: Cyclized
Sequence
LPLPL
Physicochemical Analysis

Sequence-only estimates are not provided for modified or non-standard source notation. Reported molecular properties, when available, are retained below with their source records.

Chemical Descriptors
5 reviewed residue count
Cyclized Activity
L Activity
Cyclic Activity
Cyclized Activity
Anticancer Activity
Synthetic Activity
Evidence Records 6 records
Evidence 1 Activity

Activity

IC50
IC50 = 4.68 ± 1.22 µg/ml
Anticancer
4.68

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT assay

Source & Reference

CancerPPD 2.0
CancerPPD2
2022

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 11.95 ± 0.64 µg/ml
Anticancer
11.95

Target

Liver Cancer
HepG-2
Liver

Assay & Model

MTT assay

Source & Reference

CancerPPD 2.0
CancerPPD2
2022
Evidence 3 Activity

Activity

IC50
IC50 = 14.45 ± 1.1 µg/ml
Anticancer
14.45

Target

Breast Cancer
MDA-MB-231
Breast

Assay & Model

MTT assay

Source & Reference

CancerPPD 2.0
CancerPPD2
2022
Evidence 4 Activity

Activity

IC50
IC50 = 14.5 ± 0.36 µg/ml
Anticancer
14.5

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT assay

Source & Reference

CancerPPD 2.0
CancerPPD2
2022
Evidence 5 Activity

Activity

IC50
IC50 = 7.97 ± 2.06 µg/ml
Anticancer
7.97

Target

Lung Cancer
A-549
Lung

Assay & Model

MTT assay

Source & Reference

CancerPPD 2.0
CancerPPD2
2022
Evidence 6 Activity

Activity

IC50
IC50 = 2.25 ± 0.42 µg/ml
Anticancer
2.25

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT assay

Source & Reference

CancerPPD 2.0
CancerPPD2
2022